Results 11 to 20 of about 151,502 (357)

Immunomodulatory effect of hepatitis B virus (HBV) antigens and MRSA antigens on immune response

Medical Journal of Babylon
Background: Methicillin-resistant Staphylococcus aureus is one of the most common human invaders and causes different types of illness worldwide.
Entidhar A. Hadi, Mohammad Abd-Kadhum Al-Saadi, Kaiser N. Madlum   +2 more
doaj   +2 more sources

Correlation between serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patients [PDF]

Vojnosanitetski Pregled, 2023
Background/Aim. Quantitative hepatitis B virus (HBV) surface antigen (qHBsAg) has become increasingly wide-spread in the last few years in both diagnostic and therapeutic protocols for HBV infection.
Pete Maria, Ružić Maja, Kovačević Nadica, Petrić Vedrana, Milošević Ivana, Preveden Tomislav   +5 more
doaj   +1 more source

Prevalence of hepatitis B in dental patients

Journal of Indian Academy of Oral Medicine and Radiology, 2023
Background: Hepatitis B virus (HBV) infection is one of the leading causes of death worldwide. The most important marker for HBV infection is HBsAg. In case of diagnosis of infectious disease, discordant results may have serious consequences among the ...
Ashmita Kaur R. Chawla, Tanvi R Dosi, Tushar Phulambrikar   +2 more
doaj   +1 more source

Nuclear Expression of Hepatitis B Virus X Protein Is Associated with Recurrence of Early-Stage Hepatocellular Carcinomas: Role of Viral Protein in Tumor Recurrence [PDF]

Journal of Pathology and Translational Medicine, 2016
Background: Hepatitis B virus (HBV) plays well-known roles in tumorigenesis of hepatocellular carcinoma (HCC) in infected patients. However, HBV-associated protein status in tumor tissues and the relevance to tumor behavior has not been reported.
Jing Jin, Hae Yoen Jung, Kyu Ho Lee, Nam-Joon Yi, Kyung-Suk Suh, Ja-June Jang, Kyoung-Bun Lee   +6 more
doaj   +1 more source

Hepatitis B e antigen-negative chronic hepatitis B [PDF]

Hepatology, 2001
Summary HBeAg-negative CHB has now a worldwide distribution, developing in the course of HBeAg-positive chronic HBV infection during or after the phase of HBeAg loss and its seroconversion to anti-HBe. It is caused by replicating noncytopathic HBV mutants either unable to produce HBeAg (precore mutants) or with down-regulated transcription of the ...
Hadziyannis, SJ, Vassilopoulos, D
openaire   +3 more sources

Investigation the longevity of hepatitis B surface antibody in vaccinated students of Hormozgan university of medical sciences

Iranian Journal of Microbiology, 2023
Background and Objectives: Hepatitis B is a common chronic viral infection in humans. Universal use of hepatitis B vaccine is crucial for controlling the infection, but the duration of vaccine-induced immunity remains uncertain.
Majid Najafi-Asl, Soghra Abdi, Mehdi Hassani Azad, Marzieh Norouzian   +3 more
doaj   +1 more source

Outcomes of hepatitis B immunoglobulin and hepatitis B vaccination in high-risk newborns born to HBeAg-positive mothers

Biomedical Journal, 2022
Background: To evaluate the protective efficacy of a hepatitis B (HB) vaccination program in Taiwan among high-risk children. Methods: Children born to HBeAg-positive mothers from 2001 to 2010 were invited back.
Chen-Hsuan Wu, Wei-Cheng Huang, Chien-Hung Chen, Sheng-Nan Lu   +3 more
doaj   +1 more source

The Relationship of Hepatits B Core Antibody Positivity with Demographic and Laboratory Parameters in Hemodialysis Patients

Haseki Tıp Bülteni, 2021
Aim:The presence of hepatitis B core antibody (HBcAb) is an indication of exposure to hepatitis B virus infection. We aimed to investigate the rates of positive HBcAb and its’ association with demographical and laboratory parameters among patients ...
Ilter Bozaci, Selma Tosun
doaj   +1 more source

Modulation of antigen-specific T-cells as immune therapy for chronic infectious diseases and cancer [PDF]

, 2014
Copyright: © 2014 Li, Symonds, Miao, Sanderson and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
Abraham, Ahmadzadeh, Akbar, Anderson, Baine, Barber, Baur, Belkaid, Bensinger, Bergmann, Berzofsky, Blackburn, Brooks, Brooks, Brooks, Colonna, Das, Day, Duraiswamy, Ejrnaes, Frebel, Geijtenbeek, Guidotti, Ha, Jerome, Jung, Kasprowicz, Kaufmann, Kim, Klein, Kroemer, Kroy, Larsson, Liu, Lu, Maizels, Malek, Matsuzaki, Mier, Mumprecht, Nandedkar, Nurieva, Nurieva, Ramsay, Schietinger, Schwartz, Sofra, Soldaini, Steinman, Trautmann, Vezys, Waggoner, Wedemeyer, Wilson, Yi, Zhou   +55 more
core   +6 more sources

Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections [PDF]

, 2021
Background. Chronic hepatitis B and D virus (HBV/HDV) infections can cause cancer. Current HBV therapy using nucleoside analogues (NAs) is life-long and reduces but does not eliminate the risk of cancer.
Ahlén, G, Frelin, L, Jagya, N, Johansson, M, Maravelia, P, Meuleman, Philip, Ni, Y, Pasetto, A, Pater, L, Pérez, NC, Sällberg, M, Urban, S, Verch, G, Verhoye, Lieven   +13 more
core   +1 more source